news, journals and articles from all over the world.
Experts from the Smidt Heart Institute at Cedars-Sinai, California’s premier cardiology and heart surgery provider, will present innovative research findings and lead discussions on the latest high-impact medical breakthroughs during the American College of Cardiology (ACC) Annual Scientific Session & Expo March 4-6 in New Orleans.
Marking the five-year anniversary of the $50 million gift that named the Smidt Heart Institute, Cedars Sinai is highlighting major research breakthroughs and clinical innovations pioneered by one of the nation’s leading destinations for cardiac care.
Cardiologists, cardiothoracic surgeons and interventionalists from the Smidt Heart Institute at Cedars-Sinai are presenting an array of innovative research data and leading discussions on medical breakthroughs during the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Nov. 5-7.
Susan Cheng, MD, MPH, MMSc, recalls hearing the first reports of a mysterious illness in China early last year and thinking: “This is going to be important.”
Lisa Stewart doesn’t dwell on the fact that she might be the first in the nation to undergo both mitral and tricuspid valve replacement procedures. She’s too busy counting her blessings.
Three years after the ALLSTAR clinical trial ended prematurely, the study’s data shows that treatments of cardiosphere-derived cells — the same cells used as an experimental therapy tested in COVID-19 patients — demonstrated unexpected promise in heart attack survivors. Downloadable video available.
Four of six critically ill COVID-19 (coronavirus) patients significantly improved after receiving an experimental therapeutic designed to reduce inflammation, a major cause of death from this disease, according to a case series published by Cedars-Sinai and Capricor Therapeutics. The four patients got well enough to be discharged from the hospital.
A new study from the Smidt Heart Institute at Cedars-Sinai and other centers nationwide shows that patients who underwent a minimally invasive transcatheter aortic-valve replacement (TAVR), had similar key 5-year clinical outcomes of death and stroke as patients who had traditional open-heart surgery to replace the valve. The study appears on the New England Journal of Medicine site.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu